Pharmacy company MEDA acquires a US respiratory company
Friday, 30 August 2013
Pharmacy company, Meda announced that it has signed an agreement to
acquire the US development company Acton Pharmaceuticals, Inc.
(“Acton”) including the proprietary product Aerospan.
Aerospan is an inhaler for the treatment of asthma that contains the
active substance Flunisolide. The product is approved by the FDA and
has shown in clinical studies to have a high deposition of active drug
in the airways as a result of a built-in inhalation chamber (called a
“spacer”).
In a randomized double-blind placebo-controlled study, published in the
Annals of Allergy, Asthma & Immunology, Aerospan show no
significant negative effect on linear growth in children with asthma.
This is an important feature of the Aerospan product. FDA has recently
approved the addition of data from this study in the prescribing
information.
Scancomark.com
Granscole Studios Web design Pro | Web analysis | Operations Management Consult | Marketing Consult |
Support and Contact Support | Corrections | Contact Us
Connect with Scandinavian Companies and Market